![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV
to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
|
|
|
Reported by Jules Levin EASL 2011 Berlin March 31-Apr 2
E Lawitz,1 I Jacobson,2 E Godofsky,3 G Foster,4 R Flisiak,5 M Bennett,6 M Ryan,7 JM Pawlotsky,8 Hinkle,9 J Simpson,9 J McHutchison,9 D Oldach,9 and M DeMicco10
1Alamo Medical Research, San Antonio, TX, USA; 2Weill Medical College of Cornell University, NY, NY, USA; 3Bach and Godofsky Infectious Diseases, Sarasota, FL, USA; 4Barts and The London Hopsital, London, UK;
5Klinika Chorob Zakaznych I Hepatologii, Bialystok, Poland; 6Medical Associates Research Group, San Diego, CA, USA; 7Digestive and Liver Disease Specialists, Norfolk, VA, USA; 8Henri Mondor Hospital, Paris, France;
9Gilead Sciences, Inc., Foster City, CA, USA; 10Advanced Clinical Research Institute, Anaheim, CA, USA
![EASL1.gif](../images/040611/040611-16/EASL1.gif)
![EASL2.gif](../images/040611/040611-16/EASL2.gif)
![EASL3.gif](../images/040611/040611-16/EASL3.gif)
![EASL4.gif](../images/040611/040611-16/EASL4.gif)
![EASL5.gif](../images/040611/040611-16/EASL5.gif)
![EASL6.gif](../images/040611/040611-16/EASL6.gif)
![EASL7.gif](../images/040611/040611-16/EASL7.gif)
![EASL8.gif](../images/040611/040611-16/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|